Compare SAIA & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIA | RDY |
|---|---|---|
| Founded | 1924 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.9B |
| IPO Year | 2002 | 2001 |
| Metric | SAIA | RDY |
|---|---|---|
| Price | $359.97 | $12.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 1 |
| Target Price | ★ $391.06 | $16.90 |
| AVG Volume (30 Days) | 487.9K | ★ 3.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.37 | N/A |
| Revenue | ★ $3,234,286,000.00 | N/A |
| Revenue This Year | $7.29 | $7.72 |
| Revenue Next Year | $9.08 | $3.50 |
| P/E Ratio | $69.71 | ★ $18.67 |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $249.32 | $11.36 |
| 52 Week High | $494.71 | $15.67 |
| Indicator | SAIA | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 33.15 | 41.01 |
| Support Level | $357.64 | $11.36 |
| Resistance Level | $376.30 | $14.08 |
| Average True Range (ATR) | 16.81 | 0.26 |
| MACD | -5.69 | 0.04 |
| Stochastic Oscillator | 20.99 | 54.39 |
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 210 facilities and a fleet of more than 7,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.